Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Haruka Nishiguchi"'
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 837-842 (2024)
Background: Due to its indolent biology and high estrogen receptor positivity of mucinous breast cancer, vast majority of locally advanced mucinous breast cancer (LABC) are treated with first-line endocrine therapy. Case Presentation: A 50-year-old w
Externí odkaz:
https://doaj.org/article/6070d88ab98748d6aba39af661c93a57
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 1, Pp 309-313 (2020)
A 70-year-old woman had a large mass in her right breast. Mammography displayed focal asymmetrical density in the scattered areas of fibroglandular density. Ultrasonography showed the tumor to have predominantly high-level internal echoes. Histologic
Externí odkaz:
https://doaj.org/article/aab1bfeac4714fc3b755f75fc44cba03
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 13, Iss 1, Pp 309-313 (2020)
Case Reports in Oncology, Vol 13, Iss 1, Pp 309-313 (2020)
A 70-year-old woman had a large mass in her right breast. Mammography displayed focal asymmetrical density in the scattered areas of fibroglandular density. Ultrasonography showed the tumor to have predominantly high-level internal echoes. Histologic
Autor:
Miwako Miyasaka, Mari Kawaji, Haruka Nishiguchi, Yoshiharu Nishimura, Yuka Aoishi, Shoji Oura, Yoshimitsu Hirai, Aya Shima
Publikováno v:
Breast cancer (Tokyo, Japan). 27(5)
Upper-limb lymphedema is a well-known complication of breast cancer and its treatment. This retrospective cohort study aims to determine what risk factors affect breast cancer-related lymphedema in patients with breast cancer. This retrospective stud
Publikováno v:
Breast cancer (Tokyo, Japan). 27(5)
A 54-year-old woman on methotrexate (MTX) treatment developed reddish skin change in her right breast. Mammography and ultrasound showed no masses in the breasts but bilateral mammary glands presented diffuse lower-level echoes. Only 19 days later, t
Autor:
Tatsuya, Yoshimasu, Shoji, Oura, Mitsumasa, Kawago, Yoshimitsu, Hirai, Takuya, Ohashi, Yumi, Yata, Miwako, Miyasaka, Haruka, Nishiguchi, Yuka, Aoishi, Aya, Fusamoto, Yoshiharu, Nishimura
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 45(5)
The benefits of continuing bevacizumab (BEV) beyond progressive disease (PD) in patients with non-small cell lung cancer (NSCLC) remain unclear. We present our experience of continuing chemotherapy with BEV in patients with recurrent NSCLC after surg
Autor:
Tatsuya, Yoshimasu, Takuya, Ohashi, Shoji, Oura, Yozo, Kokawa, Mitsumasa, Kawago, Yoshimitsu, Hirai, Miwako, Miyasaka, Haruka, Nishiguchi, Sayoko, Kawashima, Yumi, Yata, Mariko, Honda, Takahiro, Fujimoto, Yoshitaka, Okamura
Publikováno v:
Anticancer research. 35(11)
In the present article, we quantitatively evaluated the dose-response relationship of hormetic reactions of anticancer agents in vitro. Serial dilutions of gemcitabine, cisplatin, 5-fluorouracil, vinorelbine, and paclitaxel were administered to the A
Autor:
Yoshitaka Okamura, Mitsumasa Kawago, Shoji Oura, Koma Naito, Sayoko Hashimoto, Haruka Nishiguchi, Tatsuya Yoshimasu, Fuminori Ohta, Yoshimitsu Hirai, Rie Nakamura
Publikováno v:
Journal of Thoracic Oncology. 6(10):1658-1662
Introduction A recent large randomized controlled trial revealed that patients with lung cancer with epidermal growth factor receptor (EGFR) mutations had better prognoses when treated with the EGFR-tyrosine kinase inhibitor, gefitinib, than with cyt
Autor:
Aya Fusamoto, Yumi Yata, Mitsumasa Kawago, Haruka Nishiguchi, Shoji Oura, Takuya Ohashi, Tatsuya Yoshimasu, Yuka Aoishi, Miwako Miyasaka, Yoshiharu Nishimura, Yoshimitsu Hirai
Publikováno v:
Journal of Thoracic Oncology. 12:S2320
Autor:
Miwako Miyasaka, Aya Fusamoto, Takuya Ohashi, Shoji Oura, Yoshimitsu Hirai, Yumi Yata, Haruka Nishiguchi, Mitsumasa Kawago, Tatsuya Yoshimasu, Yuka Aoishi, Yoshiharu Nishimura
Publikováno v:
Journal of Thoracic Oncology. 12:S1963